How to protect your teeth after the fluoridation ban: DHHS offers tips
SALT LAKE CITY () — The Utah Department of Health and Human Services (DHHS) is encouraging Utahns to take action before fluoride is removed from drinking water next week.
, Fluoride Amendments, goes into effect on May 7 and will prohibit fluoridation in any public water systems across the state. The bill also allows pharmacists to prescribe fluoride tablets for those who want fluoridation.
Ahead of the ban, DHHS is providing Utahns with more information about fluoride and oral health. They also expressed their concerns that this will impact roughly 1.6 million Utahns in Salt Lake County, Davis County, and Brigham City.
MORE ABOUT THE BILL: Gov. Cox signs fluoridation ban into law – a nationwide first
'Access to accurate, evidence-based information remains essential for protecting the health of all Utahns. Oral health is a critical component of overall well-being, and we are committed to ensuring communities — especially those who may be most impacted by this change — continue to have the support and education needed to maintain good dental health,' Dr. Stacey Bank, executive medical director at DHHS, is quoted in a press release.
DHHS explains that fluoride is 'a natural mineral that helps protect your teeth and bones.' They also state that there is a natural amount of fluoride found in drinking water, but it is not generally enough to provide the benefits that protect teeth. DHHS says Utahns can provider and ask about natural fluoride levels in the drinking water.
Utahns are also recommended to complete a regular dental check-up every six months. For children six months and older, DHHS recommends fluoride varnishes two to four times a year to prevent cavities. Fluoride supplements are also recommended for children between the ages of six months and 16 years.
'I am very proud of Utah': RFK Jr. commends state officials on fluoridation ban
'We recognize the benefits of fluoride to overall health. While community water fluoridation will no longer be available, there are measures that can be taken to reduce the risk of developing cavities… We encourage Utahns to have regular checkups with a dentist or healthcare provider to make sure they are doing everything they can to protect their oral health,' said Dr. Stacey Swilling, state dental director at DHHS.
Although fluoride is most effective for children and teens, DHHS has recommendations for ensuring oral health in everybody, regardless of age.
Brush your teeth with fluoride toothpaste 2 times a day.
Floss your teeth before you go to bed.
Limit the amount of sugar you eat or drink.
Quit tobacco and nicotine use — including vaping. These products can increase the risk of gum disease, infections in your mouth, and tooth loss.
For more information on fluoride, visit the . Utahns who need a dentist can also find low-cost dental clinics near them through the link.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Look Before You Rent webinars
SYRACUSE. N.Y. (WSYR-TV) — The city of Syracuse is set to host two technical assistance webinars involving a tutorial on 'Look Before You Rent,' which is an online tool to help you become more educated on rental properties in Syracuse. This online map includes all the information you need about rentals. Including how to search by address or neighborhood to discover a property's status on the City's Rental Registry, Certificate of Compliance programs and any code violations or other property information. The webinars are scheduled for Tuesday, June 10, from 1:30 to 2:15 p.m. and Wednesday, June 11, from 5:30 to 6:15 p.m. Staff members will show attendees how to access and use the tool. There will also be times to ask questions and give feedback. To participate, you must register here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Prince George's County officer hospitalized after crash on Crain Highway
PRINCE GEORGE'S COUNTY, Md. () — Police in Prince George's County said part of Crain Highway is closed after an officer was involved in a crash Wednesday morning. Details are limited; however, police told DC News Now that a vehicle and a police officer's motorcycle collided shortly after 9 a.m. at the intersection of Crain Highway and Missouri Avenue. Aisha Braveboy projected winner for Prince George's County executive Two people who were inside the vehicle were not hurt. The officer was taken to the hospital with non-life-threatening injuries, according to police. First responders urge drivers to avoid the area and find alternative routes until the crash is cleared. DC News Now has a crew headed to the scene. Check for updates. To keep up with the latest news and weather updates, download our Mobile App on iPhone or Android. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
